Investment
Features
FeesSafety
Academy
More
Pluang+

Cboe seeks SEC approval for first U.S. 3x leveraged Bitcoin and Ether ETFs, targeting short-term traders.

Market News
14 Aug 2026
Coincu
View Source
Bullish
pluang ai news

Cboe has filed for SEC approval to launch the first U.S.-listed ETFs offering triple-leveraged exposure to Bitcoin and Ether. These 3x leveraged ETFs aim to deliver three times the daily price movement of the underlying cryptocurrencies, making them higher-risk products designed for short-term trading rather than long-term holding. The SEC's decision will be crucial in determining whether these new leveraged crypto ETFs can enter the market, potentially expanding options for investors seeking amplified crypto exposure. This move follows other recent crypto ETF filings, highlighting ongoing innovation and regulatory scrutiny in the crypto fund space.

More News

OptimumBank's price target raised to $11 amid strong financial growth and profitability.

OptimumBank's price target raised to $11 amid strong financial growth and profitability.

Industrial Alliance Securities raised OptimumBank Holdings' price target from $7.00 to $11.00, signaling a 15.24% potential upside. The bank shows strong financial health with a 2.04% ROAA, 20.34% ROAE, and a 4.57% net interest margin. Its loans grew...

Analyst Insights
Bullish
46 minutes ago
Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.

Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Analyst Insights
Bearish
1 hour ago
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured

Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

Market News
Bullish
2 hours ago
Life360 director Morin Brit sells 15,582 shares for $1 million

Life360 director Morin Brit sells 15,582 shares for $1 million

Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...

Market News
Bearish
2 hours ago
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.

AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App